Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors. AK150 is currently the only ILT2/ILT4/CSF1R trispecific antibody under development globally...
Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer
LISMORE, Australia, March 16, 2026 /PRNewswire/ -- Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment for high-grade glioma, one of the most aggressive forms of brain cancer. Backed by...
SUBANG JAYA MEDICAL CENTRE RANKED AMONG THE WORLD’S TOP 250 HOSPITALS AND TOP 10 REGIONALLY IN NEWSWEEK’S 2026 RANKING
KUALA LUMPUR, Malaysia, March 16, 2026 /PRNewswire/ -- Subang Jaya Medical Centre (SJMC) has been named among the Top 250 hospitals globally and top 10 regionally in Newsweek's World's Best Hospitals 2026, placing it among a select group of leading hospitals worldwide. The recognition highlights SJMC's commitment to international standards of clinical care and patient outcomes, further strengthening its...
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational PET imaging agent for the characterization...
Spring Into Healthy Breathing: Varon Offers Tips for Travel and Wellness with Oxygen Support
NEW YORK, March 15, 2026 /PRNewswire/ -- Spring is here, bringing warmer weather, outdoor adventures, and family travel. For individuals who rely on supplemental oxygen, enjoying the season safely requires preparation and the right equipment. VARON is sharing expert guidance for breathing health and travel while highlighting its lineup of home oxygen concentrators...
Vimgreen’s Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis (MASH), by the China's Center for Drug Evaluation (CDE). This achievement represents the second clinical indication for the company's...
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research Next-generation drug candidates against sarcopenia Next generation drug candidates for dry age-related macular degeneration SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026...
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for the year ended December 31, 2025, and provide a business update on March 30, 2026. The Company will hold live...
CityUHK researchers unveil the mystery of “Asian Flush” mechanism, pioneering new directions in precision treatment for heart attacks
HONG KONG, March 13, 2026 /PRNewswire/ -- Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known as "Asian Flush Syndrome". This ALDH2 genetic mutation is more than just a metabolic defect; it conceals a deadly cardiovascular risk. While the medical community has long observed that carriers of this mutation suffer more severe heart damage during...
BioDlink Named “Emerging CDMO of the Year” at the 2026 Asia-Pacific Biopharma Excellence Awards
BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU, China, March 13, 2026 /PRNewswire/ -- BioDlink, an innovation-driven Contract Development...
